1. Scrip
  2. >>Archive

Merck KGaA names new head of biosimilars unit

 
• By Lucie Ellis-Taitt

Darmstadt, Germany-headquartered Merck KGaA has named Boehringer Ingelheim's former head of biopharmaceuticals, Simon Sturge, head of its biosimilars unit – effective 1 March 2014. Mr Sturge will be based at the unit in Canton de Vaud, Switzerland and will report to Stefan Oschmann, a member of Merck's executive board responsible for the company's pharmaceutical businesses. Prior to Boehringer Ingelheim Mr Sturge was CEO of Dutch biotech-company OctoPlus.

Darmstadt, Germany-headquartered Merck KGaA has named Boehringer Ingelheim's former head of biopharmaceuticals, Simon Sturge, head of its biosimilars unit – effective 1 March 2014. Mr Sturge will be based at the unit in Canton de Vaud, Switzerland and will report to Stefan Oschmann, a member of Merck's executive board responsible for the company's pharmaceutical businesses. Prior to Boehringer Ingelheim Mr Sturge was CEO of Dutch biotech-company OctoPlus.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.